CD209 and neoplasm: Such approaches may be further optimized by coupling intravesical adenoviruses encoding cytokines with bispecific antibodies targeting immune checkpoints, offering potential to overcome immunosuppressive barriers like DC-SIGN + macrophages in the tumor microenvironment (TME).